Fulltext

Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study

Erne, Paul ; Schoenenberger, Andreas W. ; Zuber, Michel ; Burckhardt, Dieter ; Kiowski, Wolfgang ; Dubach, Paul ; Resink, Therese ; Pfisterer, Matthias

In: European Heart Journal, 2007, vol. 28, no. 17, p. 2110-2117

Ajouter à la liste personnelle
    Titre
    • Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study
    Auteur
    • Erne, Paul. Kantonsspital, Luzern, Switzerland
    • Schoenenberger, Andreas W.. University Hospital, Bern, Switzerland
    • Zuber, Michel. Kantonsspital, Luzern, Switzerland
    • Burckhardt, Dieter. University Hospital, CH-4031 Basel, Switzerland
    • Kiowski, Wolfgang. Klinik Im Park, Zurich, Switzerland
    • Dubach, Paul. Rhätisches Kantonsspital, Chur, Switzerland
    • Resink, Therese. University Hospital, CH-4031 Basel, Switzerland
    • Pfisterer, Matthias. University Hospital, CH-4031 Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • European Heart Journal, 2007, vol. 28, no. 17, p. 2110-2117. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290006
    Summary
    Aims To determine the effect of anti-ischaemic drug therapy on long-term outcomes of asymptomatic patients without coronary artery disease (CAD) history but silent exercise ST-depression. Methods and results In a randomized multicentre trial, 263 of 522 asymptomatic subjects without CAD but at least one CAD risk factor in whom silent ischaemia by exercise ECG was confirmed by stress imaging were asked to participate. The 54 (21%) consenting patients were randomized to anti-anginal drug therapy in addition to risk factor control (MED, n = 26) or risk factor control-only (RFC, n = 28). They were followed yearly for 11.2 ± 2.2 years. During 483 patient-years, cardiac death, non-fatal myocardial infarction, or acute coronary syndrome requiring hospitalization or revascularization occurred in 3 (12%) of MED vs. 17 (61%) of RFC patients (P < 0.001). In addition, MED patients had consistently lower rates of exercise-induced ischaemia during follow-up, and left ventricular ejection fraction remained unchanged (−0.7%, P = 0.597) in contrast to RFC patients in whom it decreased over time (−6.0%, P = 0.006). Conclusion Anti-ischaemic drug therapy and aspirin seem to reduce cardiac events in subjects with asymptomatic ischaemia type I. In such patients, exercise-induced ST-segment depression should be verified by stress imaging; if silent ischaemia is documented, anti-ischaemic drug therapy and aspirin should be considered